Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.

摘要: In metastatic colorectal cancer (mCRC), liver-limited disease (LLD) is associated with a higher chance of metastectomy leading to long-term survival. However, limited data describes the prognostic and predictive relevance initially unresectable LLD regard targeted first-line therapy. The present analysis investigated in mCRC patients treated therapy against either epidermal growth factor receptor (EGFR) or vascular epithelial (VEGF). was performed based on FIRE-3, randomized phase III trial comparing chemotherapy FOLFIRI plus cetuximab (anti-EGFR) bevacizumab (anti-VEGF) RAS wild-type (WT) mCRC. Of 400 patients, 133 (33.3%) had 267 (66.8%) non-LLD. Median overall survival (OS) significantly longer compared non-LLD (36.0 vs. 25.4 months; hazard ratio [HR] = 0.66; 95% confidence interval [CI]: 0.51-0.87; p = 0.002). multivariate also including secondary hepatic resection as time-dependent variable, status independently for OS (HR = 0.67; CI: 0.50-0.91; 0.01). As assessed by interaction tests, treatment benefit from independent objective response rate (ORR), early tumour shrinkage ≥20% (ETS), depth (DpR) (all > 0.05). conclusion, could be identified RAS-WT mCRC, which no since over status.